March Biosciences is developing MB-105, a CD5-targeted CAR-T cell therapy aimed at relapsed and refractory T cell lymphoma; MB-105 has orphan drug designation and is in a Phase 2 trial. The company emphasizes a shorter, simpler, and more robust manufacturing process and has partnered with Cell Therapy Manufacturing Center (CTMC) and Volnay Therapeutics to address manufacturing risk. March positions itself as the most advanced cell therapy product in the T cell lymphoma space and plans to expand its pipeline into additional indications. Management estimates a US addressable market of about $6 billion annually, with the initial indication representing roughly $3 billion. The company has faced a challenging fundraising environment and has focused on clinical data and manufacturing de-risking to attract partners and investors. Financially, March has sufficient resources to complete its company-sponsored Phase 2a and pursue additional pipeline development based on its recent financing runway. March Biosciences is a Houston, TX-based clinical-stage biotechnology company led by CEO Sarah Hein focused on addressing cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a chimeric antigen receptor T-cell (CAR-T) therapy targeting CD5, a protein widely expressed in both normal and malignant T-cells including T-cell leukemias and lymphomas. Because CD5 is present on healthy T-cells, it has been a challenging target; MB-105 has been engineered to preserve healthy T-cells while maintaining potency against CD5-positive tumor cells. MB-105 is being evaluated in an ongoing Phase 1 trial conducted by the Baylor College of Medicine Cell and Gene Therapy Center, where it has demonstrated a favorable safety profile and encouraging early efficacy in relapsed T-cell lymphoma and T-cell acute lymphoblastic leukemia patients. The company intends to use new funding to accelerate an upcoming Phase 2, open-label, multi-center trial assessing MB-105 in CD5-positive relapsed/refractory T-cell lymphoma; patients will receive one dose and be followed for a minimum of 12 months. March Biosciences raised $4.8M from Cancer Focus Fund.

Total raised

$34M

Funding rounds

2

Latest round

Series A

Latest activity

May 2025